Clinical Trials for Docetaxel (Taxotere)

9 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TherapeuticVICCGI1283
02/14/2013
A Randomized, Multicenter, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel or Paclitaxel) in Patients with Previously Treated Locally Advanced or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction
TherapeuticVICCTHN1281
01/23/2013
An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC)
TherapeuticVICCTHN1262
01/07/2013
An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer
TherapeuticVICCTHN1122
08/21/2012
Open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
TherapeuticVICCBRE1157
05/01/2012
A Randomized Multicenter, Double-blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with operable HER2-Positive Primary Breast Cancer
TherapeuticECOGBRES1007
01/10/2012
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and Her 2 Neu Negative Breast Cancer with Recurrence Score of 25 or Less.
TherapeuticECOGHNE1305
03/04/2009
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
TherapeuticVICCTHO0730
10/15/2007
A Phase II Trial of Celecoxib plus Chemotherapy [Docetaxel or Pemetrexed] in Patients with Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer (SPORE)
TherapeuticECOGTHOE1505
08/30/2007
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC).

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.